title: Staphylococcal osteomyelitis--a comparison of co-amoxiclav with clindamycin and flucloxacillin in an experimental rat model.
abstract: A rat model of Staphylococcus aureus osteomyelitis was used to compare treatment with co-amoxiclav, flucloxacillin and clindamycin. Co-amoxiclav (amoxycillin/clavulanic acid 200/50 mg/kg), flucloxacillin (200 mg/kg) and clindamycin (50 mg/kg) were injected subcutaneously tds for 28 days, commencing 14 days after infection. Eight days after cessation of treatment, high numbers of staphylococci were recovered from the infected tibiae of all control rats. All treatments, at clinically achievable concentrations, significantly (P < 0.05) reduced the bone bacterial titres. However, 50% of tibiae from co-amoxiclav-treated animals were sterile, compared with 17% and 25% from flucloxacillin- or clindamycin-treated animals respectively. Histopathological examination of tibiae reflected the bacteriological results, and showed that the severity of the osteomyelitis was greatly reduced in antibiotic-treated animals compared with non-treated controls. Twenty-eight days after cessation of therapy, bacterial counts from co-amoxiclav and clindamycin-treated animals remained significantly (P < 0.05) lower than those of non-treated controls, although the gross and microscopic appearance of clindamycin and flucloxacillin-treated tibiae suggested that recrudescence of the infection may have occurred. The results of this study demonstrated that co-amoxiclav was as effective as flucloxacillin and clindamycin in the treatment of an experimental chronic staphylococcal osteomyelitis.
authors.affiliation: SmithKline Beecham Pharmaceuticals, Brockham Park, Betchworth, Surrey, UK.
authors.forename: J
authors.initials: J
authors.lastname: Gisby
authors.forename: A S
authors.initials: AS
authors.lastname: Beale
authors.forename: J E
authors.initials: JE
authors.lastname: Bryant
authors.forename: C D
authors.initials: CD
authors.lastname: Toseland
mesh_terms: D000658:Amoxicillin / Q000493:pharmacokinetics / Q000627:therapeutic use; D019980:Amoxicillin-Potassium Clavulanate Combination; D000818:Animals; D002969:Clavulanic Acids / Q000493:pharmacokinetics / Q000627:therapeutic use; D002981:Clindamycin / Q000493:pharmacokinetics / Q000627:therapeutic use*; D004195:Disease Models, Animal; D004359:Drug Therapy, Combination / Q000627:therapeutic use*; D005436:Floxacillin / Q000493:pharmacokinetics / Q000627:therapeutic use*; D008297:Male; D010019:Osteomyelitis / Q000188:drug therapy* / Q000473:pathology; D051381:Rats; D013203:Staphylococcal Infections / Q000188:drug therapy* / Q000473:pathology; D013211:Staphylococcus aureus / Q000187:drug effects; D013977:Tibia / Q000473:pathology
chemical_list: D002969:Clavulanic Acids; D002981:Clindamycin; D005436:Floxacillin; D019980:Amoxicillin-Potassium Clavulanate Combination; D000658:Amoxicillin